TiumBio Co., Ltd. (KOSDAQ:321550)
South Korea · Delayed Price · Currency is KRW 5,500.00
-70.00 (-1.26%)
At close: Jan 27, 2026
TiumBio Revenue
TiumBio had revenue of 3.12B KRW in the quarter ending September 30, 2025, with 175.77% growth. This brings the company's revenue in the last twelve months to 9.32B, up 21.54% year-over-year. In the year 2024, TiumBio had annual revenue of 6.79B with 38.65% growth.
Revenue (ttm)
9.32B
Revenue Growth
+21.54%
P/S Ratio
19.55
Revenue / Employee
n/a
Employees
n/a
Market Cap
182.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.79B | 1.89B | 38.65% |
| Dec 31, 2023 | 4.90B | -4.22B | -46.27% |
| Dec 31, 2022 | 9.12B | 9.06B | 15,952.75% |
| Dec 31, 2021 | 56.80M | -992.15M | -94.59% |
| Dec 31, 2020 | 1.05B | -64.05M | -5.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CORESTEMCHEMON | 20.13B |
| BIO-FD&C | 18.82B |
| QuadMedicine | 13.11B |
| Kangstem Biotech | 12.77B |
| Bio Solution | 8.27B |
| TegoScience | 6.15B |
| NovMetaPharma | 1.30B |
| curacle co.,ltd. | 1.14B |